HYCOR Biomedical Delivers Value Beyond the Test to Clinicians Worldwide


HYCOR is a global manufacturer and supplier of high-quality in vitro diagnostics products. Through a series of acquisitions since its founding in 1981, the company has expanded its presence into Allergy and Autoimmune products, which are used in clinical laboratories, hospitals and doctors' offices worldwide. Among these products, HYCOR markets the HYTEC™ and AUTOSTAT™ brands. Headquartered in Indianapolis, Indiana, HYCOR has additional offices in Garden Grove, California and Kassel, Germany. HYCOR is a privately held corporation majority owned by Linden Capital Partners.

HYCOR’s Corporate Mission Drives a Strategy for Success


HYCOR finds success as a worldwide leader in clinical diagnostics by:

  • Listening to and learning from our customers
  • Evolving with the changing global healthcare market place
  • Providing value and quality to the laboratory
  • Providing the latest clinically relevant diagnostic and disease management tools that allow professionals to guide patient management

Vital Clinical Value Through In vitro Diagnostic Products for Allergy and Autoimmune


HYCOR is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. The company is committed to developing new products and technologies that bring actionable information to laboratories and clinicians in a cost-effective manner, improving patient care and contributing to healthcare cost containment.

The company offers a comprehensive line of systems and testing products for in vitro allergy and autoimmune disorders. This includes the HYTEC 288 Plus system, which uses HYCOR’s chemical reagents and assays for the diagnosis and management of allergies. HYCOR uses its Enzyme Immunoassay (EIA) for Allergy. AUTOSTAT kits Enzyme-linked immuno sorbent assay (ELISA) are used for detecting autoimmune disorders.

Roche to Distribute HYCOR KOVA® Urinalysis Product.


17 May 2012 - Roche has entered into a five year collaboration agreement with a manufacturer of diagnostic products, HYCOR Biomedical.

Under the agreement, Roche will distribute HYCOR's KOVA urinalysis plastics and controls products with its urinalysis tests and platforms.

KOVA urinalysis controls include specially engineered Glasstic slides and sample tubes which are used to validate the performance of urine chemistry test strips and readers and to help focus microscopic sediment analysis.

Roche professional diagnostics head Colin Brown said, "Concurrent with our global leading position in in-vitro diagnostics, the expanded agreement with HYCOR emphasizes our commitment of bringing industry expertise in providing high-quality urinalysis products to health professionals at hospital laboratories."

HYCOR president and CEO Dick Aderman said, "This agreement allows us to expand our presence into an additional 85 markets, further underscoring the value it brings to the healthcare professionals and patients it serves."

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

HYCOR Broadens Diagnostic Offerings, Announces Agreements to License Biomarkers for Celiac Disease and Rheumatoid Arthritis


25 July 2011 - GARDEN GROVE, Calif., - HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products, today announced that it has signed an agreement with Eurospital-a manufacturer of pharmaceutical products, medical-surgical and diagnostic devices-to license its tTG biomarker in all countries covered by the patent (excluding the US and Canada) for its ability to diagnose celiac disease. HYCOR today also announced that it has signed an agreement with AXIS-SHIELD-a developer of in vitro diagnostic tests-to license its anti-CCP biomarker for its ability to diagnose rheumatoid arthritis (RA). Customers will have access to these critical biomarkers from HYCOR in the coming weeks.

"We are pleased to offer HYCOR customers a tool to help clinicians diagnose these devastating, chronic diseases," said Dick Aderman, CEO, HYCOR. "We look forward to continuing to expand our diagnostic offerings, ensuring customers are able to meet the ever-changing needs of the healthcare professionals they serve."

Celiac disease is a condition that damages the lining of the small intestine and prevents it from absorbing nutrients properly, leading to malnutrition. The symptoms of celiac disease vary from one patient to the next, which poses challenges to healthcare professionals in the accurate diagnosis of the disease. If left untreated celiac disease can cause other complications, including autoimmune disease, anemia and hypoglycemia, and, in some instances, certain types of intestinal cancer. 1

RA is a chronic autoimmune disease that leads to joint inflammation, as well as inflammation of the surrounding tissue. Early diagnosis of the disease, and early aggressive treatment, can delay joint destruction and prevent symptoms from worsening. 2

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

About Eurospital
Founded in 1948, Eurospital is a scientific organization active in such sectors as diagnostics, pharmaceutical industry and hospital practice. The Company is located in Trieste (ITALY), a city hosting a number of international research centers, which are now gaining increasing scientific importance in the field of biotechnology. The company is focused on the diagnosis of celiac diseases, gastroenterology, infectious diseases, septic infections.

About AXIS-SHIELD
Axis-Shield (www.axis-shield.com) is an international and innovative in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specializes in the supply of instruments and tests for the rapidly growing physician's office testing market and the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, and diabetes.

1. PubMed Health, available at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001280/, accessed July 15, 2011
2. PubMed Health, available at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001467/, accessed July 15, 2011

×

HYCOR Appoints Sean-Xavier Neath as Chief Medical Officer to Support Expansion of Product Lines and Enhance Customer Support Offerings


19 July 2011 - GARDEN GROVE, Calif., - HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products, today announced that Sean-Xavier Neath, M.D., Ph.D., has been appointed as Chief Medical Officer (CMO). In this role, Dr. Neath will support the company as it works to expand its product lines and provide additional support for customers.

"We are pleased to welcome Dr. Neath to the HYCOR team and are confident he will have great impact on key areas of our business," said Dick Aderman, CEO, HYCOR. "Given his diverse background in the academic, clinical and business sectors we look forward to learning from his experience and leveraging his unique perspective during this important time of growth for the company."

Dr. Neath brings extensive knowledge and leadership in the pharmaceutical and diagnostics industries having served in medical affairs positions for a number of leading companies, including BRAHMS USA and Biosite. During his time at BRAHMS USA, Dr. Neath lead new product development strategies, including clinical trial design and regulatory submission planning. In addition, Dr. Neath was responsible for medical education, marketing and reimbursement program development. In his role at Biosite, Dr. Neath provided strategic counsel to the business development, marketing, sales and R&D teams and also developed educational curricula for physician clients.

"I'm pleased to join the HYCOR team to identify product development opportunities and work to expand the customer support services that HYCOR customers value most," said Dr. Neath.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

HYCOR Expands Board of Directors to Support Growth in Key Areas


16 May 2011 - GARDEN GROVE, Calif., - HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, together with owner Linden, LLC, today announced the appointments of Vijay Aggarwal, Ph.D. and James Koziarz, Ph.D., to its Board of Directors as part of its global growth strategy.

"We are thrilled to welcome Drs. Aggarwal and Koziarz to the HYCOR team and are confident they will have meaningful impact in areas critical for the company's continued growth," said Richard Novak, Chairman of HYCOR's Board of Directors, and Operating Partner at Linden, LLC. "Both of these gentlemen have extensive backgrounds in clinical diagnostics for market leading companies, and we are certain that HYCOR will benefit from their guidance in the short and near term."

Dr. Aggarwal brings more than 30 years of experience and leadership in the pharmaceutical and diagnostics industries, having served in senior management positions for a number of leading companies, including Quest Diagnostics, IBT Laboratories and SmithKline Beecham. As Director, Dr. Aggarwal will support the HYCOR management team in a variety of capacities with a particular focus on channel development in clinical laboratories.

Dr. Koziarz joins HYCOR's Board after a distinguished 25 year career at Abbott Laboratories, where he held several senior management and executive positions, including Corporate Vice President for Diagnostic Products Research & Development. Dr. Koziarz is also an active advisor to several leading life sciences companies. As Director, Dr. Koziarz will support the HYCOR management team on next generation assay and platform development strategies for global customers.

"We are pleased to have the opportunity to partner with these two leaders in clinical diagnostics and are confident it will benefit HYCOR, the healthcare professionals and patients our products serve," said Dick Aderman, CEO, HYCOR. "Our executive team has begun working with each of them on key initiatives currently underway and we look forward to the value they will bring to our business."

HYCOR's CEO, Dick Aderman, also brings extensive leadership in the clinical diagnostics arena, having spent more than 30 years serving in senior management positions for a number of clinical diagnostic companies, including Roche Diagnostics Corporation, Boehringer Mannheim Corporation and Dade International.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.

×

Life Science Company Relocating California Headquarters to Indiana


27 April 2011 - INDIANAPOLIS - HYCOR Biomedical, Inc., a manufacturer of diagnostic products for clinical laboratories, announced today plans to relocate its headquarters from Garden Grove, Calif. to Central Indiana, adding 12 jobs by the end of the year and up to 20 jobs by 2013.

This is the second California company to relocate its headquarters to Indiana in the past two years. In 2009, Fleetwood RV moved from Riverside, Calif. to Decatur, Ind., creating 300 new jobs. Additional companies including Beckman Coulter have consolidated operations from California in recent years.

"During tough economic times, Indiana welcomed new jobs from companies consolidating from a couple dozen or more U.S. states and a handful of foreign countries. HYCOR is the latest example of the benefits of maintaining fiscal discipline and a low-cost business environment," said Mitch Roob, Secretary of Commerce and chief executive officer of the Indiana Economic Development Corporation.

HYCOR entered the diagnostics market in 1984 and currently provides urinalysis, allergy and autoimmune testing products for clinical laboratories, hospitals and doctors' offices worldwide.

"Given Indiana's central location, the exceptional life sciences talent based here, as well as the economic incentives being offered by the state, we believe this is the ideal time for HYCOR to relocate as our business continues to grow," said Richard Aderman, president and chief executive officer of HYCOR.

The Indiana Economic Development Corporation offered HYCOR up to $640,000 in performance-based tax credits based on the company's job creation plans. HYCOR is currently leasing space at 3021 East 98th St. in Indianapolis while it finalizes a long-term location in Central Indiana in the coming months.

HYCOR is the second life sciences company to move into Central Indiana in just more than one month. In March, Advion BioServices Inc. announced plans to establish a $6.1 million laboratory at the Purdue Research Park at Ameriplex, adding 49 immediate jobs and up to 66 jobs by 2015.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

About IEDC
Created by Governor Mitch Daniels in 2005 to replace the former Department of Commerce, the Indiana Economic Development Corporation is governed by a 12-member board chaired by Governor Daniels. Mitch Roob serves as the chief executive officer of the IEDC. For more information about IEDC, visit www.iedc.in.gov.

1. Data on file

×

HYCOR Biomedical Announces New Branding Initiative

Innovative Social Media Event Launching HYCOR You Tube Channel To Debut at AACC Clinical Lab Expo


GARDEN GROVE, CA, July 27, 2010 - HYCOR Biomedical Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets used in clinical laboratories throughout the world, today announced the launch of a new branding initiative with the launch of a HYCOR You Tube Channel as part of its continuing transformation to a broad diagnostics company. This and other initiatives will debut at the American Association for Clinical Chemistry Clinical Lab Expo July 27 - 29.

"We continue to build on the historical core strengths of high quality, cost effective lab based solutions that HYCOR was built upon as we lead the company forward to an exciting future," said Dick Aderman, CEO of HYCOR. "Since gaining control of our destiny by becoming an independent organization just a few months ago we are creating a revitalized organization with our partners at Linden that is more energized, collaborative, and better focused to develop new products and new applications in the allergy and autoimmune sectors for our global customers. The innovative social media event planned for this meeting represents a symbolic break from our past and highlights the exciting opportunities ahead of us."

The launch of the HYCOR You Tube Channel will occur at the HYCOR Booth #4200 and will feature a number of industry professionals discussing current topics, including changes in the clinical laboratory, personalized medicine, diagnostics and the role of social media as a means of real time medical communication presented by eFuturist and author Douglas Goldstein.

In addition, live and pre-recorded guest interviews with participants from the clinical laboratory, corporations, the media and patients will be featured and posted to the HYCOR You Tube Channel from the Expo.

"The goal of our program and the new HYCOR You Tube Channel is to attract new business partners, create collaborations and enhance our dialogue with the industry," said Richard Hockins, Vice President of Sales and Marketing for HYCOR. "We currently do business with the top reference and hospital labs and also distributors around the globe. Based on this track record, we believe we can expand our market share rapidly with the use of new media. Our AACC event will allow the market to experience the new HYCOR and see us as a dynamically changing organization taking a proactive approach to product development and the awareness of the HYCOR brand."

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

EFuturist Douglas Goldstein Discusses EHealth And Social Media At AACC Clinical Lab Expo In Anaheim


ANAHEIM, CA, July 26, 2010EFuturist and author Douglas Goldstein, an internationally recognized expert in healthcare strategy, e-commerce and e-care, will speak about the power of the internet and how it is shaping healthcare trends at the HYCOR Biomedical Booth # 4200 at the AACC Clinical Lab Expo in Anaheim, CA on Tuesday, July 27th at the Anaheim Convention Center.

As a thought leader in the area of e-Healthcare who has written 10 books on healthcare management and the internet, Goldstein frequently discusses how the internet is radically changing healthcare. Goldstein will focus on the role of social media as a means of real time medical communication and the trends that will transform medical education. Reporters interested in speaking with Goldstein about this and other transformative healthcare topics are welcome to visit the HYCOR booth on July 27th.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

HYCOR Biomedical Announces Senior Executive Appointments

Steve Johnson As Director Quality and Regulatory Affairs And Mark Van Cleve, PhD As Director Research and Development Further Strengthens Management Team


GARDEN GROVE, CA, July 22, 2010 - HYCOR Biomedical Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets used in clinical laboratories throughout the world, today announced new senior executive appointments as the company continues its transformation into a leading global diagnostics company. Steve Johnson was named Director of Quality and Regulatory Affairs and Mark Van Cleve as Director of Research and Development.

"Both Steve and Mark are highly skilled executives with significant experience in our industry and we are very pleased that they share our vision in building HYCOR as a global leader in the diagnostics field," said Dick Aderman, CEO of HYCOR. "We place a high premium on attracting outstanding talent to our new organization and the addition of their respective talents marks another key milestone in the ongoing transformation of HYCOR."

Mr. Johnson comes to HYCOR with more than 25 years of in vitro diagnostics experience with Abbott Laboratories where he worked with Clinical Chemistry, Hematology and Immunoassay products. He has held a series of leadership positions at Abbott, most recently as Site Quality Head and Management Representative at the Abbott - South Pasadena, CA facility. He also served as Manager of Supplier and Operations Quality Assurance, Hematology Customer Support, and Technical Operations. He is a member of the American Chemical Society (ACS) and American Society for Quality (ASQ). Mr. Johnson holds a number of certifications, including: ASQ Certified Manager of Quality/Organizational Excellence, ASQ Certified Biomedical Auditor, and ISO 9001 Certified Lead Auditor. Mr. Johnson has a BS in Chemistry from University of Wisconsin - Stevens Point.

Dr. Van Cleve has extensive experience in diagnostics R&D and project management as well as managing R&D teams. He served with Chiron Corporation (Novartis) from 2000 to 2007 and most recently was Applications Development Manager at Agilent Technologies, Inc., former parent of HYCOR, where he managed process/product engineering and R&D for the HYCOR division and managed a team of scientists. As Principal Scientist at Chiron, he managed R&D teams and project development for a number of Hepatitis B diagnostic kits. He also spent seven years with BD Bioscience as a Senior Scientist involved in the development of blood diagnostic products. Dr. Van Cleve received his Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign. He holds a number of patents.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

HYCOR Biomedical Announces Appointment of Richard Hockins As Vice President, Sales and Marketing


GARDEN GROVE, CA, July 9, 2010 - HYCOR Biomedical Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets used in clinical laboratories throughout the world, today announced the appointment of Richard Hockins to the position of Vice President, Sales and Marketing.

Mr. Hockins comes to HYCOR with over 15 years of management experience in sales and marketing in the pharmaceutical, life sciences and in vitro diagnostics sectors. He has held various leadership positions to include Director of Marketing and Service BRAHMS biomarkers unit of Thermo Fisher Scientific, Director of Marketing Exagen Diagnostics, Inc., as well as sales and marketing roles for Roche Diagnostics, and Gen-Probe.

Mr. Hockins has a Bachelor's of Science from the University of Tennessee, Martin, a Master's in Biomedical Research from East Tennessee State University, and an MBA from Anderson University.

"The immediate goal for HYCOR is to build an outstanding brand in the clinical diagnostic market," said Dick Aderman, HYCOR Biomedical president and chief executive officer. "Richard is a results-driven sales and marketing professional, and we are delighted to have him lead our global sales and marketing team. His expertise will contribute to the success of our new allergy product launches, enhance our efforts to support our clinical and distributor business partners while helping HYCOR build our global market share in allergy, autoimmune, urinalysis and infectious disease."

Commenting on his new position, Mr. Hockins, said, "With my extensive experience in medical sales and marketing in the clinical laboratory sector, I am excited to be a part of helping to reinvigorate this outstanding organization under Dick's leadership. As an independent company we will better leverage our technology to improve patient care and create a stronger competitor in the diagnostics industry."

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

Linden Acquires HYCOR Biomedical Business from Agilent Technologies


CHICAGO and SANTA CLARA, CA, Feb. 3, 2010 - Linden LLC, a Chicago-based healthcare private equity firm, today announced it has acquired HYCOR Biomedical Inc. from Agilent Technologies (NYSE: A). HYCOR develops, manufactures and markets in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets. Agilent acquired HYCOR through its acquisition of Stratagene in 2007. The terms of the agreement were not disclosed.

Founded in 1981 and based in Garden Grove, California, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. A series of acquisitions since its founding have expanded the company's presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT® brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service.

"We believe HYCOR has great opportunities outside of the Agilent portfolio," said Nick Roelofs, President of Agilent's Life Sciences Group. "HYCOR is an innovative, profitable and growing business, but it does not fit the core focus of our life science business. Agilent is pleased that Linden is the buyer because of its strong healthcare and diagnostics expertise coupled with its track record of investing in and growing businesses."

Richard Novak, a Linden Operating Partner and former Chief Operating Officer of Laboratory Corporation of America (NYSE: LH), will serve as Chairman of HYCOR. "The HYCOR platform is well-positioned to compete in the high-growth segments of in vitro diagnostics for allergy and autoimmune testing," said Novak. "Additionally, HYCOR's market leadership in urinalysis products provides the business an attractive platform for international expansion."

Thomas Weisel Partners LLC acted as exclusive financial advisor to Agilent for this transaction.

About Agilent Technologies
Agilent Technologies Inc. is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 17,000 employees serve customers in more than 110 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available on the Web at www.agilent.com.

About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, Focused Health Solutions, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

HYCOR Establishes Center of Operations in Kassel, Germany to Provide Dedicated Support to European Distributors and Customers


17 Sep 2012 - HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, today announced the opening of its European center of operations located in Kassel, Germany. The facility primarily houses field and technical service as well as customer service functions.

"As we continue to branch out internationally, we are thrilled to reestablish our physical presence in Europe with this new facility in Kassel, Germany," said Dick Aderman, CEO, HYCOR. "The opening of this facility is part of our global growth strategy and marks an important step in strengthening our support and commitment to EMEA (Europe, the Middle East and Africa) customers. The facility will be instrumental in handling current and future distributor and customer needs."

The new center of operations, which opened in early August, supports HYCOR’s expansion in EMEA and demonstrates HYCOR’s commitment and dedication to this important market.

Contact information
Hycor Europe / Bio Crest B.V.
Waldauer Weg 84
34253 Kassel - Lohfelden
Germany
Phone: +49 561 816 7000 - 0
Fax: +49 561 816 7000 - 99
Customer Service: cseurope@hycorbiomedical.com
Technical & Application Service:techserviceseurope@hycorbiomedical.com

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com. ×

HYCOR Awarded with Novation Supplier Agreement

Agreement Provides More Than 65,000 Healthcare Members Served by Novation with the Ability to Purchase Allergy and Autoimmune Testing from HYCOR


5 Jun 2012 - HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products, today announced that it has been awarded a two year supplier agreement, effective June 1, 2012, by Novation – the leading healthcare supply chain expertise and contracting company for the more than 65,000 members of VHA Inc. and UHC, two national healthcare alliances, and Provista, LLC. The two-year agreement will provide the healthcare members Novation serves with access to allergy and autoimmune laboratory testing from HYCOR.

"Our nearly 30 years in the in vitro allergy and autoimmune testing market translates to value beyond the test for the members served by Novation,” said Dick Aderman, CEO, HYCOR. “We are pleased to work with Novation to offer the members these important allergy and autoimmune testing options at a competitive price."

Allergy disease is the fifth leading chronic disease in the United States, with an estimated 60 million Americans (roughly 1 in 5) suffering from one or more allergy types. The symptoms of allergy can appear in the nose, ears, lungs, skin, digestive system or all over. Early diagnosis and treatment of allergy have been shown to modify the course of the disease and help prevent subsequent development of other more serious conditions.

An autoimmune disorder is a condition that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders and diagnosis is a complex process.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

×

HYCOR Appoints New Chief Financial Officer


GARDEN GROVE, CA, 8 Jan 2013 - HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, today announced that Ed Cordell has joined the company as Chief Financial Officer.

"Ed's three decade career brings a set of invaluable skills that we need as we embark on our next phase of growth,” said Dick Aderman, CEO, HYCOR. “His tested financial and strategy expertise will help ensure HYCOR remains on a strong path to meet our customer and investors expectations. We welcome Ed and are thrilled to have such a high caliber executive join our team."

Cordell is a seasoned financial executive with more than 30 years of experience and a proven record of success. He joins HYCOR from Given Imaging, Inc., a world leader in GI medical devices and pioneer of capsule endoscopy, where he was Chief Financial Officer with responsibility for the North and South American regions. Cordell brings extensive expertise in operational, accounting and financial challenges of building high-growth and high-tech businesses with a majority of focus on medical device companies.

Cordell has also held senior financial executive positions with Gravograph, the world’s leading maker and seller of machines, accessories and materials used in the engraving industry, Novoste Corporation, who was the first company to develop and market a radiation therapy system to treat restenosis and CryoLife, a producer of implantable living human tissues and surgical adhesives. Cordell received his Bachelor of Science degree from the University of Tennessee. "I'm very excited to join HYCOR during this crucial time as the company moves to expand the business," said Cordell. "I look forward to joining a superb leadership team and working with them to support the continued growth."

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.

HYCOR Divests Urinalysis Business to Increase Focus on Allergy and Autoimmune Markets


19 Feb 2013 - HYCOR Biomedical, Inc. ("HYCOR"), a leading manufacturer and marketer of in vitro diagnostic products for the global allergy and autoimmune markets, today announced that it has sold its urinalysis business to an affiliate of One Rock Capital Partners, Laurel Crown Partners, and StoneCreek Capital. The sale includes the KOVA® system of urinalysis products. HYCOR is a portfolio company of Linden Capital Partners ("Linden").

“The divestiture of the urinalysis business represents an important step in our growth strategy for HYCOR and allows us to focus exclusively on the growing, global allergy and autoimmune sectors of in vitro diagnostics,” said Richard Novak, Chairman of HYCOR’s Board of Directors, and Operating Partner at Linden.

The urinalysis business will be named Kova International, Inc. and will continue to operate out of its Garden Grove, California manufacturing facility under the leadership of Vance Mitchell, who has more than 25 years of experience with the Kova urinalysis business.

“With this action we are better positioned to grow our pipeline of allergy and autoimmune diagnostic products to serve the needs of our customers, whether they are leading clinical laboratories or integrated health networks,” said Dick Aderman, President and CEO of HYCOR. “Healthcare providers are increasingly looking to innovations in in vitro diagnostics to provide accurate diagnosis of these prevalent and costly conditions.”

Allergies represent the fifth leading chronic disease in the United States, with an estimated 60 million Americans suffering from one or more allergy types. Moreover, it is estimated that 30-40% of the world population is now affected by one or more allergic conditions. The symptoms of allergy can appear in the nose, ears, lungs, skin, digestive system or other parts of the body. Early diagnosis and treatment of allergy have been shown to modify the course of the disease and help prevent subsequent development of other more serious conditions. An autoimmune disorder is a condition that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders and diagnosis is a complex process. Focusing on the allergy and autoimmune markets provides important synergies as the diagnostics for these disease categories share commonalities such as platform, assay development and manufacturing, and also target the same end user and areas of the laboratory.

The transaction includes the transfer of urinalysis assets and employees. Financial terms of the transaction were not disclosed. Houlihan Lokey served as exclusive financial advisor to HYCOR and Kirkland & Ellis LLP provided legal advice to HYCOR for the transaction.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. Visit Linden Capital Partners at www.lindenllc.com. ×

HYCOR


17 May 2011 -

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

1. Data on file

×

Request form for healthcare professionals


Validation in progress
×